Pelthos Therapeutics Inc. (NYSE:PTHS) on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for ...

Soleno Therapeutics's previously-announced public offering of 2.35 million shares was priced at $85 apiece, resulting in $200 million in proceeds. The biopharmaceutical company said on Thursday that ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: ...

TG Therapeutics is currently about 2% above a 36.84 entry from a consolidation. The stock has an 81 EPS Rating, which means ...

Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare ...

Liquidia shipped its first FDA-approved product, Yutrepia for pulmonary hypertension in June entering market worth several ...

MILAN--(BUSINESS WIRE)--Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable cancers and genetic conditions, announces its launch ...

GeneCentric Therapeutics has earned an initial $8m in a Series C funding round, marking a step towards the launch and commercialisation of GenomicsNext, an integrated platform for comprehensive liquid ...

Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ is investigational ...

BioXcel Therapeutics, Inc. has just released results for the fourth quarter of 2022. Some analysts have expressed doubts about the commercial success of its Igalmi launch. The good growth in forms ...

Venture capitalists are funneling $191 million into Maze Therapeutics, a biotech startup seeking answers to the question of why some people with disease-causing gene mutations don’t get sick.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: ...